ArticleTranslational cancer research2025
Clinical characteristics and long-term prognosis of primary mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma in the small intestine.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small intestine primary mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma (DLBCL) are relatively rare types of non-Hodgkin's lymphoma. This study aimed to analyze the clinical characteristics and long-term prognosis of these two diseases based on the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Patients diagnosed with small intestine MALT and DLBCL from 2000 to 2021 were included. Propensity score matching (PSM) was used to minimize selection bias. The Kaplan-Meier method and Cox proportional hazards models were utilized to evaluate the effects of various clinical characteristics on overall survival (OS) and cancer-specific survival (CSS). Results: A total of 2,748 patients were enrolled, including 2,362 with DLBCL and 386 with MALT. Compared to DLBCL patients, MALT patients were younger, had a higher proportion of females, and presented at earlier American Joint Committee on Cancer (AJCC) stages. Before PSM, the MALT cohort demonstrated significantly better OS [hazard ratio (HR) 0.54, 95% confidence interval (CI): 0.46-0.64, P<0.001] and CSS (HR 0.34, 95% CI: 0.26-0.45, P<0.001) than the DLBCL cohort. Specifically, 5-year OS rates were 80.1% for MALT and 57.6% for DLBCL, while 5-year CSS rates were 90.0% and 67.8%, respectively. Even after PSM, the MALT group maintained significantly superior OS (HR 0.55, 95% CI: 0.44-0.68, P<0.001) and CSS (HR 0.37, 95% CI: 0.26-0.52, P<0.001). Cox regression analysis identified age and AJCC stage as prognostic factors for OS in MALT patients, while race and AJCC stage were prognostic for CSS. For DLBCL patients, age, year of diagnosis, AJCC stage, chemotherapy, and marital status were significant prognostic factors for both OS and CSS. Conclusions: Patients with small intestine MALT lymphoma have a better prognosis than those with DLBCL, and AJCC staging is a significant prognostic factor, highlighting the importance of early diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.